SeDeM tool-driven full factorial design for osmotic drug delivery of tramadol HCl: Formulation development, physicochemical evaluation, and in-silico PBPK modeling for predictive pharmacokinetic evaluation using GastroPlus™
The study is based on using SeDeM expert system in developing controlled-release tramadol HCl osmotic tablets and its in-silico physiologically based pharmacokinetic (PBPK) modeling for in-vivo pharmacokinetic evaluation. A Quality by Design (QbD) based approach in developing SeDEM-driven full factorial osmotic drug delivery was applied. A 24 Full-factorial design was used to make the trial formulations of tramadol HCl osmotic tablets using NaCl as osmogen, Methocel K4M as rate controlling polymer, and avicel pH 101 as diluent. The preformulation characteristics of formulations (F1-F16) were determined by applying SeDeM Expert Tool. The formulation was optimized followed by in-vivo predictive pharmacokinetic assessment using PBPK “ACAT” model of GastroPlus™. The FTIR results showed no interaction among the ingredients. The index of good compressibility (ICG) values of all trial formulation blends were ≥5, suggesting direct compression is the best-suited method. Formulation F3 and F4 were optimized based on drug release at 2, 10, and 16 h with a zero-order kinetic release (r2 = 0.992 and 0.994). The SEM images confirmed micropores formation on the surface of the osmotic tablet after complete drug release. F3 and F4 were also stable (shelf life 29.41 and 23.46 months). The in vivo simulation of the pharmacokinetics of the PBPK in-silico model revealed excellent relative bioavailability of F3 and F4 with reference to tramadol HCl 50 mg IR formulations. The SeDeM expert tool was best utilized to evaluate the compression characteristics of selected formulation excipients and their blends for direct compression method in designing once-daily osmotically controlled-release tramadol HCl tablets. The in-silico GastroPlus™ PBPK modeling provided a thorough pharmacokinetic assessment of the optimized formulation as an alternative to tramadol HCl in vivo studies..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in Pharmacology - 13(2022) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Muhammad Talha Saleem [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Controlled release |
|---|
| doi: |
10.3389/fphar.2022.974715 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ001109324 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ001109324 | ||
| 003 | DE-627 | ||
| 005 | 20230307021425.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fphar.2022.974715 |2 doi | |
| 035 | |a (DE-627)DOAJ001109324 | ||
| 035 | |a (DE-599)DOAJb1039c5735424c36a3ed0e70d856e84b | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RM1-950 | |
| 100 | 0 | |a Muhammad Talha Saleem |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SeDeM tool-driven full factorial design for osmotic drug delivery of tramadol HCl: Formulation development, physicochemical evaluation, and in-silico PBPK modeling for predictive pharmacokinetic evaluation using GastroPlus™ |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The study is based on using SeDeM expert system in developing controlled-release tramadol HCl osmotic tablets and its in-silico physiologically based pharmacokinetic (PBPK) modeling for in-vivo pharmacokinetic evaluation. A Quality by Design (QbD) based approach in developing SeDEM-driven full factorial osmotic drug delivery was applied. A 24 Full-factorial design was used to make the trial formulations of tramadol HCl osmotic tablets using NaCl as osmogen, Methocel K4M as rate controlling polymer, and avicel pH 101 as diluent. The preformulation characteristics of formulations (F1-F16) were determined by applying SeDeM Expert Tool. The formulation was optimized followed by in-vivo predictive pharmacokinetic assessment using PBPK “ACAT” model of GastroPlus™. The FTIR results showed no interaction among the ingredients. The index of good compressibility (ICG) values of all trial formulation blends were ≥5, suggesting direct compression is the best-suited method. Formulation F3 and F4 were optimized based on drug release at 2, 10, and 16 h with a zero-order kinetic release (r2 = 0.992 and 0.994). The SEM images confirmed micropores formation on the surface of the osmotic tablet after complete drug release. F3 and F4 were also stable (shelf life 29.41 and 23.46 months). The in vivo simulation of the pharmacokinetics of the PBPK in-silico model revealed excellent relative bioavailability of F3 and F4 with reference to tramadol HCl 50 mg IR formulations. The SeDeM expert tool was best utilized to evaluate the compression characteristics of selected formulation excipients and their blends for direct compression method in designing once-daily osmotically controlled-release tramadol HCl tablets. The in-silico GastroPlus™ PBPK modeling provided a thorough pharmacokinetic assessment of the optimized formulation as an alternative to tramadol HCl in vivo studies. | ||
| 650 | 4 | |a tramadol | |
| 650 | 4 | |a SeDeM diagram expert system | |
| 650 | 4 | |a PBPK | |
| 650 | 4 | |a osmotic tablet | |
| 650 | 4 | |a controlled release | |
| 650 | 4 | |a gastroplus | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 700 | 0 | |a Muhammad Harris Shoaib |e verfasserin |4 aut | |
| 700 | 0 | |a Rabia Ismail Yousuf |e verfasserin |4 aut | |
| 700 | 0 | |a Farrukh Rafiq Ahmed |e verfasserin |4 aut | |
| 700 | 0 | |a Kamran Ahmed |e verfasserin |4 aut | |
| 700 | 0 | |a Fahad Siddiqui |e verfasserin |4 aut | |
| 700 | 0 | |a Zafar Alam Mahmood |e verfasserin |4 aut | |
| 700 | 0 | |a Muhammad Sikandar |e verfasserin |4 aut | |
| 700 | 0 | |a Muhammad Suleman Imtiaz |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Frontiers in Pharmacology |d Frontiers Media S.A., 2010 |g 13(2022) |w (DE-627)DOAJ000099732 |x 16639812 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fphar.2022.974715 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/b1039c5735424c36a3ed0e70d856e84b |z kostenfrei |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fphar.2022.974715/full |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1663-9812 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 | ||